Table 3 Mean number of injections and proportion of eyes without a yearly injection.
Characteristics | Total eyes | Typical nAMD | PCV | ||||||
|---|---|---|---|---|---|---|---|---|---|
Ranibizumab | Aflibercept | p value | Ranibizumab | Aflibercept | p value | Ranibizumab | Aflibercept | p value | |
Number of Injections, mean ± SD | |||||||||
1 year | 4.12 ± 1.62 | 4.51 ± 1.53 | 0.080* | 4.20 ± 1.81 | 4.51 ± 1.53 | 0.342* | 4.05 ± 1.41 | 4.51 ± 1.55 | 0.119* |
2 years | 2.00 ± 1.87 | 1.84 ± 1.51 | 0.585* | 2.00 ± 2.08 | 1.91 ± 1.60 | 0.843* | 2.00 ± 1.69 | 1.76 ± 1.43 | 0.527* |
3 years | 1.64 ± 1.90 | 1.51 ± 1.65 | 0.726* | 1.73 ± 2.12 | 1.32 ± 1.70 | 0.452* | 1.56 ± 1.73 | 1.71 ± 1.62 | 0.734* |
4 years | 1.35 ± 1.64 | 1.64 ± 1.92 | 0.716* | 1.56 ± 1.78 | 1.21 ± 2.02 | 0.544* | 1.17 ± 1.51 | 1.78 ± 1.83 | 0.217* |
Mean yearly injections, mean ± SD | 2.92 ± 1.66 | 3.01 ± 1.46 | 0.692* | 3.14 ± 1.98 | 3.01 ± 1.59 | 0.701* | 2.70 ± 1.24 | 3.01 ± 1.33 | 0.222* |
Proportion of eyes without a yearly injection, n (%) | |||||||||
2 years | 28/85 (32.9%) | 17/64 (26.6%) | 0.401† | 15/40 (37.5%) | 9/35 (25.7%) | 0.275† | 13/45 (28.9%) | 8/29 (27.6%) | 0.903† |
3 years | 32/66 (48.5%) | 19/43 (44.2%) | 0.660† | 15/30 (50.0%) | 11/22 (50.0%) | 1.000† | 17/36 (47.2%) | 8/21 (38.1%) | 0.503† |
4 years | 29/57 (50.9%) | 19/37 (51.4%) | 0.964† | 13/27 (48.1%) | 12/19 (63.2%) | 0.314† | 16/30 (53.3%) | 7/18 (38.9%) | 0.332† |
